HLA‐associated antiepileptic drug‐induced cutaneous adverse reactions-Reference-Cited by-同舟云学术

HLA‐associated antiepileptic drug‐induced cutaneous adverse reactions

Published:2019-04-09 Issue:6 Volume:93 Page:417-435
ISSN:2059-2302
Container-title:HLA
language:en
Short-container-title:HLA

Author:

Mullan Kerry A.¹^ORCID,Anderson Alison²,Illing Patricia T.¹^ORCID,Kwan Patrick²³,Purcell Anthony W.¹,Mifsud Nicole A.¹^ORCID

Affiliation:

1. Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular BiologyMonash University Clayton Victoria Australia

2. Department of Neuroscience, Central Clinical SchoolMonash University Clayton Victoria Australia

3. Department of NeuroscienceThe Alfred Hospital Melbourne Victoria Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Genetics,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tan.13530

Reference109 articles.

1. RockvilleM. Reducing and preventing adverse drug events to decrease hospital costs: research in action.2001.http://www.ahrq.gov/research/findings/factsheets/errors-safety/aderia/index.html. Accessed August 10 2018.

2. Which drugs cause preventable admissions to hospital? A systematic review

3. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia

4. Severe Adverse Cutaneous Reactions to Drugs

5. Cutaneous drug reactions;Svensson CK;Pharmacol Rev,2001

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Éosinophiles et toxidermies;Annales de Dermatologie et de Vénéréologie - FMC;2024-07

2. Clinical observation and analysis of rash caused by lacosamide in children with epilepsy;Seizure: European Journal of Epilepsy;2024-04

3. Cultural and Ethnic Perspectives in Psychopharmacology;Tasman’s Psychiatry;2024

4. Viral Vector-Based Gene Therapy for Epilepsy: What Does the Future Hold?;Molecular Diagnosis & Therapy;2023-12-16

5. Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity;JAMA Network Open;2023-10-26